GlassScriptPhysician profile
Carlos Zapata
NPI 1669480802
$5,069.14
in general payments reported to CMS, 2019-2025
27 companies · $1,092 in 2025
The $1,092 reported for 2025 was more than what 89% of providers received nationally.
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $929 · 2020: $561 · 2021: $371 · 2022: $510 · 2023: $544 · 2024: $1,061 · 2025: $1,092.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,697.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,697.23 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $1,069.40 | 2019-2025 | Evenity, Tepezza |
| Abbvie INC. | $672.74 | 2019-2025 | Creon |
| Lilly USA, LLC | $615.32 | 2020-2025 | Mounjaro, Zepbound |
| Alexion Pharmaceuticals, INC. | $356.82 | 2024-2025 | Strensiq |
| Horizon Therapeutics Plc | $270.32 | 2021-2023 | Tepezza |
| Medtronic, INC. | $261.29 | 2021-2024 | Minimed 780g |
| Novo Nordisk INC | $218.34 | 2020-2025 | Ozempic, Rybelsus |
| Astrazeneca Pharmaceuticals LP | $176.40 | 2019-2024 | Farxiga |
| Sanofi-Aventis U.S. LLC | $170.17 | 2019-2022 | |
| Corcept Therapeutics | $157.98 | 2022-2023 | Korlym |
| Kowa Pharmaceuticals America, INC. | $139.42 | 2019-2021 | |
| Abbott Laboratories | $129.89 | 2019-2023 | Proclaim, Freestyle Libre 3 |
| Ethicon US, LLC | $124.32 | 2019 | |
| Janssen Scientific Affairs, LLC | $114.30 | 2024 | Stelara |
| Allergan, INC. | $111.31 | 2020 |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| E.R. Squibb & Sons, L.L.C. | $105.84 | 2025 | Camzyos |
| Valeritas, INC. | $95.15 | 2019 | |
| Dexcom, INC. | $74.76 | 2020-2021 | |
| Merck Sharp & Dohme LLC | $44.97 | 2019 | |
| Amneal Pharmaceuticals LLC | $35.67 | 2025 | Unithroid |
| Ipsen Biopharmaceuticals, INC | $25.77 | 2025 | Iqirvo |
| Regeneron Healthcare Solutions, INC. | $23.57 | 2023 | Evkeeza |
| Grifols USA, LLC | $19.46 | 2022 | |
| Xeris Pharmaceuticals, INC. | $17.09 | 2024 | Recorlev |
| Tandem Diabetes Care, INC. | $13.50 | 2020 | |
| Medtronic Minimed, INC. | $13.04 | 2020 | |
| Covidien LP | $12.30 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Carlos Zapata listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.